Enzon Pharmaceuticals Inc (ENZN) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
20 COMMERCE DRIVE, SUITE 135 CRANFORD, NJ 07016 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 47,012 | 46,982 | 47,641 | 48,142 | 5,446 | 6,500 | |||
| Cash and cash equivalents | 47,012 | 46,982 | 47,641 | 48,142 | 5,446 | 6,500 | |||
| Receivables | 485 | 970 | |||||||
| Other current assets | 331 | 405 | 85 | 59 | 62 | 70 | |||
| Other undisclosed current assets | 31 | 7,000 | |||||||
| Total current assets: | 47,343 | 47,387 | 47,726 | 48,232 | 5,993 | 14,540 | |||
| Noncurrent Assets | |||||||||
| Nontrade receivables | 485 | 970 | |||||||
| Deferred income tax assets | 359 | 202 | ✕ | ||||||
| Total noncurrent assets: | 359 | 202 | 485 | 970 | |||||
| Other undisclosed assets | 28 | ||||||||
| TOTAL ASSETS: | 47,702 | 47,589 | 47,754 | 48,232 | 6,478 | 15,510 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 439 | 424 | 403 | 412 | 423 | 517 | |||
| Accounts payable | 331 | 331 | 331 | 302 | 324 | 439 | |||
| Accrued liabilities | 108 | 93 | 72 | 110 | 99 | 78 | |||
| Other undisclosed current liabilities | 1,275 | 1,275 | |||||||
| Total current liabilities: | 1,714 | 1,699 | 403 | 412 | 423 | 517 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1,714 | 1,699 | 403 | 412 | 423 | 517 | |||
| Equity | |||||||||
| Equity, attributable to parent | 3,505 | 3,407 | 4,868 | 7,360 | 6,055 | 14,993 | |||
| Common stock | 742 | 742 | 742 | 742 | 442 | 442 | |||
| Additional paid in capital | 73,433 | 74,708 | 75,983 | 78,006 | 75,690 | 83,649 | |||
| Accumulated deficit | (70,670) | (72,043) | (71,857) | (71,388) | (70,077) | (69,098) | |||
| Total equity: | 3,505 | 3,407 | 4,868 | 7,360 | 6,055 | 14,993 | |||
| Other undisclosed liabilities and equity | 42,483 | 42,483 | 42,483 | 40,460 | |||||
| TOTAL LIABILITIES AND EQUITY: | 47,702 | 47,589 | 47,754 | 48,232 | 6,478 | 15,510 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2,261 | 26 | 701 | 52 | 207 | 6,918 | ||
| Net investment income | 2,261 | |||||||
| Gross profit: | 2,261 | 26 | 701 | 52 | 207 | 6,918 | ||
| Operating expenses | (1,044) | (1,058) | (1,170) | (1,357) | (1,180) | (1,063) | ||
| Other undisclosed operating loss | (2,261) | |||||||
| Operating income (loss): | (1,044) | (1,032) | (469) | (1,305) | (973) | 5,855 | ||
| Nonoperating income (Other Nonoperating income) | 646 | 7 | 1 | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (1,044) | (386) | (462) | (1,304) | (973) | 5,855 | ||
| Other undisclosed income from continuing operations before income taxes | 2,261 | |||||||
| Income (loss) from continuing operations before income taxes: | 1,217 | (386) | (462) | (1,304) | (973) | 5,855 | ||
| Income tax expense (benefit) | 156 | 200 | (7) | (7) | (6) | (6) | ||
| Income (loss) from continuing operations: | 1,373 | (186) | (469) | (1,311) | (979) | 5,849 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (469) | (1,311) | (979) | 5,849 | |
| Net income (loss) attributable to parent: | 1,373 | (186) | (469) | (1,311) | (979) | 5,849 | ||
| Preferred stock dividends and other adjustments | (1,275) | (1,275) | (2,023) | (460) | ||||
| Net income (loss) available to common stockholders, diluted: | 98 | (1,461) | (2,492) | (1,771) | (979) | 5,849 | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 1,373 | (186) | (469) | (1,311) | (979) | 5,849 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 1,373 | (186) | (469) | (1,311) | (979) | 5,849 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.